NCT07480863 2026-03-18
Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT07448324 2026-03-04
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06583837 2026-02-27
Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
Fudan University
Phase 2 Active not recruiting